Predictors of hot flushes in postmenopausal women who receive raloxifene therapy

Aldrighi, José Mendes; Quail, Deborah; Levy-Frebault, Jacques; Águas, Fernanda; Kosian, K; Garrido, Lurdes; Goux, B. Bosio-Le; Saráchaga, Max; Graebe, Alice; Nino, Antonio; Nickelsen, Thomas

doi:10.1016/j.ajog.2004.04.042

Cited by 17 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our post hoc subgroup analysis also supported the notion that phytoestrogenic herbal Fufang could be more effective for younger patients, suggesting that the influence of the timing of XLGB treatment should be elucidated in further research. This may also imply that herbal Fufang, similar to selective estrogen receptor modulators [1,2], could be more effective for the prevention of postmenopausal osteoporosis in the first decade after the onset of menopause, and such preventive trials in early postmenopausal women should be explored in the future.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

“…Chemically synthesized selective estrogen receptor modulators, such as raloxifene, were developed in part to avoid the aforementioned side effects [1,2]. Other alternative candidates reported recently were natural phytoestrogenic isoflavones derived from leguminous plants (e.g., soy) [14].…”

Section: Introductionmentioning

confidence: 99%

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…One predictor, higher BMI, has previously been shown to significantly predict increased subjective hot flash frequency in post-menopausal women 26. A randomized, controlled study of raloxifene indicated that the highest number of subjective hot flashes at baseline was seen in women who were fewer years postmenopausal, who had had a surgical menopause, and who had received previous estrogen or estrogen/progestin therapy 27. However, these variables did not consistently predict hot flashes over time after initiating raloxifene.…”

Section: Discussionmentioning

confidence: 99%

Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy

et al. 2009

View full text Add to dashboard Cite

Objective-Hot flashes are valuable indicators of physiologic condition and drug effect; however, subjective and objective measures do not always agree. No study has examined both subjective and objective hot flashes in women prescribed aromatase inhibitors. The study (1) compared subjective and objective hot flash measures, (2) examined changes in subjective and objective hot flashes over time, and (3) evaluated predictors of change in hot flashes in aromatase inhibitor-treated women.Design-Subjects (n=135) were enrolled in a randomized clinical trial comparing exemestane and letrozole for the treatment of breast cancer. Hot flashes were assessed prior to starting drug and 1, 3, and 6 months later. Subjects wore a sternal skin conductance monitor for ≥ 24 hours at each time point. With each perceived hot flash, women pressed an event button and rated intensity and bother in a paper diary.Results-Subjects were a mean age of 60 years and mainly Caucasian (92%). Across time points, monitor hot flashes were (1) significantly more frequent than diary and/or event button flashes (p<. 05) and (2) moderately correlated with subjective measures (.35< r <.56). Monitor hot flashes did not significantly change over time with aromatase inhibitor therapy, whereas both diary and event button frequency significantly varied but in dissimilar patterns (51% non-linear). No consistent predictors of hot flashes across measures or time points were identified.Conclusions-Findings indicated dissimilarities between subjective and objective measures of hot flashes. Despite statistical significance, there was little clinically meaningful change in hot flashes after initiating aromatase inhibitor therapy.Address for correspondence and reprints: Julie L. Otte, PhD, RN, Indiana University, 1111 Middle Drive NU236, Indianapolis, IN 46220, (email) jlelam@iupui.edu. Objective and subjective hot flash measures were analyzed after initiation of two aromatase inhibitors for the treatment of breast cancer. Findings indicated dissimilarities among measures, hot flash frequency and hot flash intensity and bother did not significantly change over time, diary and event button flashes significantly changed but in dissimilar patterns, and few consistent predictors of change in hot flashes were identified.

show abstract

“…84,87 In the MORE and CORE studies, 12.6% of women receiving raloxifene reported hot flushes compared with 6.9% in the placebo group (P G 0.0001). 84 In a placebo-controlled study of 487 postmenopausal women, a shorter time since menopause, surgical menopause, and previous HT use were significant predictors of having at least 14 hot flushes per week while receiving raloxifene therapy.…”

Section: Adverse Eventsmentioning

confidence: 96%

Preventing osteoporosis in symptomatic postmenopausal women

Gallagher

Levine

2011

Menopause

View full text Add to dashboard Cite

Osteoporosis is a common postmenopausal disease that has a substantial impact on the quality of life of older women and is associated with significant morbidity and mortality. There are various options for preventing osteoporosis in postmenopausal women, and all are associated with differing benefit-risk profiles. Estrogen therapy (in hysterectomized women) and estrogen/progestogen therapy (in nonhysterectomized women) are the most effective treatments available for the relief of vasomotor and urogenital symptoms in postmenopausal women and provide significant protection against osteoporotic fractures. Selective estrogen receptor modulators reduce bone loss and prevent vertebral fractures without endometrial or breast stimulation. Raloxifene, the only selective estrogen receptor modulator approved for osteoporosis prevention and treatment, significantly reduces vertebral but not nonvertebral or hip fractures. Bisphosphonates prevent bone loss and vertebral fractures; however, not all bisphosphonates have been shown to prevent nonvertebral fractures. Selective estrogen receptor modulators and bisphosphonates are not effective for menopausal symptoms. Hormone therapy should be considered as first-line therapy for preventing bone loss and fractures in early postmenopausal women who are symptomatic; other options include selective estrogen receptor modulators and bisphosphonates, especially in older, nonsymptomatic women. Future therapies are likely to include newer selective estrogen receptor modulators, combinations of estrogen with selective estrogen receptor modulators, and denosumab.

show abstract

Predictors of hot flushes in postmenopausal women who receive raloxifene therapy

Cited by 17 publications

References 29 publications

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis

Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy

Preventing osteoporosis in symptomatic postmenopausal women

Contact Info

Product

Resources

About